FUJIFILM Biosciences Unveils HEK293 Perfusion Medium for Gene Therapy
First commercial cell culture solution tailored for HEK293 cells in perfusion, enabling high-density growth, scalable viral vector production, and consistent quality for advanced therapies.
FUJIFILM Biosciences has unveiled BalanCD HEK293 Perfusion A, the first commercially available cell culture medium tailored specifically for HEK293 cells in perfusion processes. The launch marks a significant step forward in enabling scalable, high-quality viral vector production for gene therapies.
HEK293 cells are widely used in upstream bioprocessing for gene therapy, offering strong growth rates and high transfection efficiency. BalanCD HEK293 Perfusion A builds on these advantages, supporting high-density (HCD) and intensified cultures while maximizing cell growth, viability, and productivity. The medium is designed for a broad range of applications, from Adeno-Associated Virus (AAV) and Lentivirus (LV) production to transient protein and recombinant protein expression.
Optimized for steady-state and intensified perfusion, the medium is compatible with multiple transfection methods and cell retention devices, making it versatile across workflows. Its continuous processing capabilities support both laboratory-scale research and large-scale commercial manufacturing. By improving process consistency and scalability, FUJIFILM’s new solution addresses key bottlenecks in gene therapy development.
“With BalanCD HEK293 Perfusion A medium, we have introduced a new way to advance gene therapies, building on a family of high-performing HEK293 products to provide more consistent, high-quality resources across the treatment spectrum,” said Erik Vaessen, Chief Business Officer at FUJIFILM Biosciences. “This innovative approach is another example of how we are working with our partners to bring breakthrough therapies to more patients worldwide.”
The introduction of BalanCD HEK293 Perfusion A reflects FUJIFILM Biosciences’ commitment to supporting the next generation of advanced therapies, providing reliable solutions that help reduce costs, maximize efficiency, and accelerate the path from research to clinical and commercial production.
Author
BioFocus Newsroom